Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

 

Trial Summary:

A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Supported By:

AGO Research GmbH

Eligibility:

Female patients, aged >18 with advanced endometrial carcinoma suitable for chemotherapy, with histologically confirmed diagnosis of epithelial ovarian carcinoma or fallopian tube carcinoma or primary peritoneal carcinoma

Registration ID:

NCT01837251

Participation:

Australia, Belgium, France, Austria, Germany, UK

Australian Lead Group:

ANZGOG

Status:

Follow-up

Activation Date:

01/07/2014

Chairs:

Dr Catherine Shannon

Contact:

ovar2.21.study@sydney.edu.au